Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11781247 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  A Phase II Study of Rituximab Combined With CHOP in T-Cell Angio-Immunoblastic Lymphoma
Condition: Untreated T-Cell Angioimmunoblastic Lymphoma
Intervention: Drug: Rituximab + CHOP regimen

Indicates status has not been verified in more than two years